M&A is back on the rise and Healthcare is no exception. With a record number of drugs coming off patent in the next 24 months and the traditional pharmaceutical model showing signs of age, we expect to see even more deal activity. But the success of deals in this industry has been limited, with experience showing that integration is difficult. An independent survey of industry executives reported that with each case so unique, no specific structure is best suited for all integrations.
Executives highlighted the need for a tailored approach that accounts for the strategic intent, organizational differences, and the assets being acquired (e.g. technology, clinical projects, launched products, small focused or large diverse company). With M&A success so mixed (for acquirer shareholders), boards have become more active in vetting the “how” of potential transactions and not only the “why.”